Obermatt

Flags

Financial distress

Kenvue

NYQ:KVUE · US49177J1025
Personal ProductsX-Large

360

27
EV / EBIT60
Price / Owner Earnings35
Owner Earnings Yield45
Dividend Yield95
Price/Sales51
EV / Gross Profit30
Price/Book35
Return on Capital61
Cash Return on Capital42
Return on Equity60
EBIT Margin75
Gross Profitability15
Cash Conversion63
Accruals51
Owner Earnings Margin57
Sales growth49
Profit Growth98
Long-Term EPS Growth67
Owner Earnings Growth63
Reinvestment26
Price momentum36
Debt load38
Refinancing70
Debt Payback15
Liquidity78
Analyst ratings12
Opinion Changes50
Price Target Upside24
Market mood3
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kenvue clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPersonal Products
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded2022
Employees13,395
Websitekenvue.com
ISINUS49177J1025
Last UpdateApr 2, 2026
Themes
Health DiagnosticsPain ManagementAllergyWomen's HealthAlternative MedicineFast-Moving Consumer GoodsNutraceuticalLifestyleWellness and RecoveryPersonal HealthWellness

Description

Kenvue Inc. operates as a pure-play consumer health company worldwide. The company is a global leader at the intersection of healthcare and consumer goods. By combining the power of science with meaningful consumer insights and the company’s digita…

Analysis

Middle-of-the-road

Kenvue Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 20.9× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 11%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is stretched. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
78
2026

All-time high

92

Mar 2026

All-time low

78

Jun 2026

Average rank

85

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
51
Price/Earnings
26
Price/Book
35
Dividend Yield
95
Value (overall)
77

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kenvue with its peers
Natera
NSQ:NTRA
39
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
NextNav
NAQ:NN
38
CountryUSA
IndustrySoftware
SizeSmall
Full Stock Analysis →
Kimberly-Clark
NSQ:KMB
32
CountryUSA
IndustryHousehold Products
SizeLarge
Full Stock Analysis →
LifeVantage
NAQ:LFVN
33
CountryUSA
IndustryPersonal Products
SizeSmall
Full Stock Analysis →
Myriad Genetics
NSQ:MYGN
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Park Dental Partners
NAQ:PARK
24
CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →